On November 7, 2024, the FDA approved a major clinical trial to explore the use of cannabis in treating PTSD symptoms among U.S. veterans. This study, known as MJP2, will examine how smoking or vaporizing cannabis impacts PTSD symptoms in 320 veterans across Michigan and two other states. The trial is funded by a $12.9 million grant from Michigan’s Cannabis Regulatory Agency and led by the Multidisciplinary Association for Psychedelic Studies (MAPS).
What Is the MJP2 Study About?
MJP2 is designed to study how cannabis is used in real-life settings to manage PTSD symptoms. This decision is especially significant as it reflects a shift in the FDA’s approach to cannabis research. Unlike traditional clinical trials, which often impose strict controls, this study will allow veterans to:
- Smoke or vaporize cannabis rather than use other methods like pills or oils.
- Adjust their dosage based on their needs each day, mimicking how many people already use cannabis.
- Use cannabis with THC levels comparable to those found in legal markets.
The goal is to generate real-world data that can help doctors better understand how cannabis can be used to treat PTSD and related conditions.
About MAPS
MAPS is a nonprofit organization dedicated to advancing psychedelic and cannabis research. Founded in 1986, MAPS has been a leader in exploring novel treatments for mental health conditions, including PTSD.
Through decades of persistence, MAPS has paved the way for innovative studies like MJP2, helping to break down barriers in medical research and create new possibilities for healing.
The Challenges in Getting FDA Approval
The journey to this trial’s approval wasn’t easy. MAPS faced resistance from the FDA over several issues, including concerns about smoking as a delivery method and the inclusion of cannabis with higher THC levels. Over three years, MAPS received five clinical hold letters from the FDA, temporarily halting the trial’s progress.
In response, MAPS submitted a Formal Dispute Resolution Request (FDRR) to challenge the FDA’s requirements. This process successfully convinced the FDA to update its approach to cannabis research, allowing MJP2 to move forward.
These negotiations also set an important precedent for other researchers, clearing the way for future studies on cannabis as a medical treatment.
Why This Matters for Veterans with PTSD
Veterans often face unique challenges when managing PTSD symptoms. While traditional treatments like therapy and medication work for some, many veterans report limited success with these options. Some turn to cannabis as a way to manage their symptoms. However, there hasn’t been enough high-quality research to understand its safety and effectiveness until now.
Dr. Sue Sisley, the principal investigator for MJP2, shared that veterans in her practice have expressed how smoking cannabis has helped them more than traditional medications. She hopes this trial will provide doctors with the data needed to create better treatment plans.
What Makes MJP2 Different?
This trial stands out because it aims to reflect real-world cannabis use. Instead of imposing rigid rules that don’t match how people actually use cannabis, MJP2 allows participants to use cannabis in ways that feel natural to them. This represents a historic step forward for medical research.
Participants in the study will be able to:
- Self-titrate, meaning they can adjust their dosage based on how they feel each day.
- Use cannabis with THC levels similar to what’s available in dispensaries.
- Smoke or vaporize cannabis, two methods commonly used by individuals managing PTSD symptoms.
These features make MJP2 a groundbreaking study that prioritizes patient needs and real-world scenarios.
A Broader Impact on Cannabis Research
The approval of MJP2 doesn’t just benefit this one trial—it’s a victory for cannabis research as a whole.
This trial could provide valuable data for doctors, regulators, and patients alike. It’s a step toward better understanding the potential benefits—and risks—of cannabis use for medical conditions like PTSD, chronic pain, and anxiety.
As MJP2 moves forward, researchers will collect data on the safety and effectiveness of cannabis for treating PTSD. The results could reshape how cannabis is viewed as a medical treatment and help guide policies around its use.
For veterans struggling with PTSD, this trial offers hope for new, effective treatment options that could improve their quality of life.
Closing Thoughts
Here at Icaro Connect, we are hopeful that this groundbreaking trial will illuminate the therapeutic potential of cannabis. Icaro Connect has long championed innovative treatments for mental health and believes studies like MJP2 could help normalize the conversation around cannabis and other alternative therapies.
In summary, the approval of the MJP2 trial marks a significant step forward in understanding how cannabis can be used to treat PTSD in veterans. With support from organizations like MAPS and Icaro Connect, this trial is a hopeful step toward creating effective, research-backed treatments that can meet the unique needs of veterans.
Author: Kasidy Grant
Hi! I'm Kasidy, a content creator for Icaro Connect. I am a Public Relations graduate of the University of Texas at Austin, and I love the work we get to do here in support of psychedelic therapy.
